Logo-apb

Journal Info:

Freq.: Quarterly

eISSN: 2251-7308 
pISSN: 2228-5881 

Permission: CC By

Platinum Open Access

(no submission or publication fees)

Powered by
Adv Pharm Bull. 2022;12(3): 490-508. doi: 10.34172/apb.2022.052
PMID: 35935056        PMCID: PMC9348538

Review Article

Nanotechnology Approaches for Enhanced CNS Drug Delivery in the Management of Schizophrenia

Rajalakshmi Rajendran 1 ORCID, Krishnakumar Neelakandha Menon 2 * , Sreeja Chandrasekharan Nair 1 * ORCID

Cited by CrossRef: 7

1- Kamyab H, Jamalpour S, Khalili E, Rajendran S. Advances in nanocarrier-based nose-to-brain drug delivery systems for neurological disorders - A comprehensive review. Powder Technology. 2026;474:122244 [Crossref]
2- Sondhi P, Lingden D, Bhattarai J, Demchenko A, Stine K. Applications of Nanoporous Gold in Therapy, Drug Delivery, and Diagnostics. Metals. 2022;13(1):78 [Crossref]
3- Rizos E, Theleritis C, Tsoporis J, Spandidos D, Katsantoni E. Janus kinase/signal transducer and activator of transcription pathway in schizophrenia (Review). Biomed Rep. 2025;24(1):1 [Crossref]
4- Rao G, Jamadar S. Development and characterization of asenapine maleate loaded nanostructured lipid carrier for improved brain delivery. Journal of Dispersion Science and Technology. 2025;:1 [Crossref]
5- Mahanta A, Gothwal A, Chaulagain B, Muolokwu C, Tagoe B, Lamsal B, Belin M, Singh J. Emerging anti-inflammatory nanosystems targeted to the brain. Nanomedicine. 2025;20(17):2237 [Crossref]
6- Madduluri S, Chigurupati V, Dronavalli S, Godavarthi L, Jadi R, Kuchukuntla M, Boggula N. ADVANCES IN NOVEL DRUG DELIVERY SYSTEMS FOR NEUROPSYCHIATRIC DISORDERS: A COMPREHENSIVE REVIEW. IND DRU. 2025;62(12):7 [Crossref]
7- Rajendran R, Kunnil A, Radhakrishnan A, Thomas S, Nair S. Current Trends and Future Perspectives for Enhanced Drug Delivery to Central Nervous System in Treatment of Stroke. Ther Deliv. 2023;14(1):61 [Crossref]
8- Ji X, Chai J, Zhao S, Zhao Y. Plant-derived polyphenolic compounds for managing schizophrenia: mechanisms and therapeutic potential. Front Pharmacol. 2025;16 [Crossref]
9- Wani S, Singh S, Sharma N, Zahoor I, Grewal S, Gupta S. Transferosome-Based Intranasal Drug Delivery Systems for the Management of Schizophrenia: a Futuristic Approach. BioNanoSci. 2024;14(4):3811 [Crossref]
10- Kato H, Shiraishi C, Hagihara M, Mikamo H, Iwamoto T. Association between voriconazole-induced visual hallucination and dopamine in an analysis of the food and drug administration (FDA) adverse event reporting system database. Sci Rep. 2024;14(1) [Crossref]
11- Mathew A, Mohapatra S, Panonnummal R. Formulation and evaluation of magnesium sulphate nanoparticles for improved CNS penetrability. Naunyn-Schmiedeberg's Arch Pharmacol. 2023;396(3):567 [Crossref]
12- Tekade A, Ratnaparkhi M, Shewale A, Shinde R, Kulkarni G, Pawar P. Design and assessment of in-situ nasal gel incorporated with nanostructured cubosomes for the targeted therapy of schizophrenia. 2025;29(3):947 [Crossref]
13- Kumar A, Keerikkadu M, Devanand Bangera P, Shetty A, Tippavajhala V, Rathnanand M. Advanced nanoparticle-enabled risperidone delivery for improved therapeutic outcomes of schizophrenia management: a review. Drug Development and Industrial Pharmacy. 2025;51(12):1727 [Crossref]